Czajka Pamela, Fitas Alex, Jakubik Daniel, Eyileten Ceren, Gasecka Aleksandra, Wicik Zofia, Siller-Matula Jolanta M, Filipiak Krzysztof J, Postula Marek
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology, Warsaw, Poland.
First Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Front Physiol. 2021 Apr 15;12:652579. doi: 10.3389/fphys.2021.652579. eCollection 2021.
MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by specific gene modifications. Platelets are the major source for circulating miRNAs, with significant regulatory potential on cardiovascular pathophysiology. MiRNAs have been shown to modify the expression of platelet proteins influencing platelet reactivity. Circulating miRNAs can be determined from plasma, serum, or whole blood, and they can be used as diagnostic and prognostic biomarkers of platelet reactivity during antiplatelet therapy as well as novel therapeutic targets in cardiovascular diseases (CVDs). Herein, we review diagnostic and prognostic value of miRNAs levels related to platelet reactivity based on human studies, presenting its interindividual variability as well as the substantial role of genetics. Furthermore, we discuss antiplatelet treatment in the context of miRNAs alterations related to pathways associated with drug response.
微小RNA(miRNA)是一类小的非编码RNA,能够通过特定的基因修饰来调节细胞功能。血小板是循环miRNA的主要来源,对心血管病理生理学具有重要的调节潜力。已表明miRNA可改变影响血小板反应性的血小板蛋白的表达。循环miRNA可从血浆、血清或全血中检测出来,它们可用作抗血小板治疗期间血小板反应性的诊断和预后生物标志物,以及心血管疾病(CVD)的新型治疗靶点。在此,我们基于人体研究综述与血小板反应性相关的miRNA水平的诊断和预后价值,介绍其个体间变异性以及遗传学的重要作用。此外,我们在与药物反应相关途径的miRNA改变的背景下讨论抗血小板治疗。